Teclistamab

Teclistamab, a bispecific IgG4 antibody, was well-tolerated and showed encouraging efficacy with durable, deepening responses in heavily-pretreated, relapse or refractory patients with multiple myeloma, Amrita Y. Krishnan, MD, FACP, told Healio in a video interview.

Teclistamab showed encouraging efficacy among patients with relapsed or refractory multiple myeloma, according to results of the phase 1 MajesTEC-1 study presented during the virtual ASCO Annual Meeting.